There has been substantial interest in the development of GLP-1 drugs and optimism about their public health effects. But some worrisome signals related to disordered eating have emerged.
How GLP-1 drugs like Ozempic quiet 'food noise' and change emotional eating patterns. What neuroimaging and behavioral research reveals about reward circuits, cravings, and building a healthier relationship with food.
Abstract Background Several Glucagon-like peptide-1 (GLP-1) receptor agonists are FDA-approved for weight loss in patients with obesity primarily through targeting gastrointestinal pathways to reduce caloric intake; however, less is known about the GLP-1 receptor agonist impact on the behavioral aspects of eating.
Potential Risks of GLP-1 Agonists. Although GLP-1 medications can be highly effective, they are not without some risks. Due to slowed gastric emptying, common side effects may include nausea, vomiting, diarrhea and constipation.
Such details provide a deeper understanding and appreciation for Glp-1 Agonists For Participation In Eating Rituals.
While GLP-1 receptor agonists are widely studied for their effectiveness in promoting weight loss, less is known about long-term weight maintenance after discontinuing the medication.
GLP-1 agonists work by imitating hormones that make people feel full for longer. (Getty Images: Mario Tama). Even for people not using the medications, media coverage "celebrating weight loss" and showing "before and after" pictures can also contribute to disordered eating, she said.
Call it agonorexia when GLP-1 agonists create an obsession with food and weight loss in a way that puts patients health at risk. Fullness that feeds an eating disorder.
